Verastem, Inc. (VSTM) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Rebecca, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Veristem Oncology Second Quarter 2025 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, Simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I will now turn the call over to Drewlissa Theana, Vice President, Corporate Communications, Investor Relations, Patient Advocacy. Please go ahead. Thank you, Operator. Welcome, everyone, and thank you for joining us today to discuss Verisim's second quarter 2025 financial results and recent business updates. Earlier today, we issued a press release detailing our financial results for the second quarter of 2025. This release, along with a slide presentation that we will reference during our call today, are available on our website. Before we begin, I would like to remind you that any statements made during this call are not historical and are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factor section in the company's most recent annual report on Form 10-K filed with the SEC. on March 28, 2025, and the current report on Form 10-Q filed today, as well as other reports filed with the SEC. Any forward-looking statements we make represent Verisem's views as of today, and we disclaim any obl...